Cardiovascular health in kratom users; a narrative review

References

• Domingo O, Roider G, Stöver A, Graw M, Musshoff F, Sachs H, Bicker W. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1–e7. doi:10.1016/j.forsciint.2016.12.020.
   PubMed Web of Science ®Google Scholar
• Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (Kratom): a survey of the literature. Brain Res Bull. 2016;126(Pt 1):41–6. doi:10.1016/j.brainresbull.2016.05.004.
   PubMedGoogle Scholar
• Vicknasingam B, Narayanan S, Beng GT, Mansor SM. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010;21(4):283–8. doi:10.1016/j.drugpo.2009.12.003.
   PubMed Web of Science ®Google Scholar
• Wang C, Walker AE. Fatal mitragynine-associated toxicity in Canada: a case report and review of the literature. Acad Forensic Pathol. 2018;8(2):340–6. doi:10.1177/1925362118782076.
   PubMedGoogle Scholar
• Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li J-H, et al. Following “the roots” of Kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries. Biomed Res Int. 2015;2015:968786–11. doi:10.1155/2015/968786.
   PubMed Web of Science ®Google Scholar
• Ya K, Tangamornsuksan W, Scholfield CN, Methaneethorn J, Lohitnavy M. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): a systematic review. Asian J Psychiatr. 2019;43:73–82. doi:10.1016/j.ajp.2019.05.016.
   PubMed Web of Science ®Google Scholar
• Leong Bin Abdullah MFI, Singh D. The adverse cardiovascular effects and cardiotoxicity of kratom (Mitragyna speciosa Korth.): a comprehensive review. Front Pharmacol. 2021;12:726003. doi:10.3389/fphar.2021.726003.
   PubMed Web of Science ®Google Scholar
• Groff D, Stuckey H, Philpott C, Van Dyke E, Silvis M, Leong SL, Bone C. Kratom use disorder: a primer for primary care physicians. J Addict Dis. 2022;40(1):131–41. doi:10.1080/10550887.2021.1950263.
   PubMed Web of Science ®Google Scholar
• Graves JM, Dilley JA, Terpak L, Brooks-Russell A, Whitehill JM, Klein TA, Liebelt E. Kratom exposures among older adults reported to U.S. poison centers, 2014-2019. J Am Geriatr Soc. 2021;69(8):2176–84. doi:10.1111/jgs.17326.
   PubMed Web of Science ®Google Scholar
• Prozialeck WC. Update on the pharmacology and legal status of kratom. J Am Osteopath Assoc. 2016;116(12):802–9. doi:10.7556/jaoa.2016.156.
   PubMed Web of Science ®Google Scholar
• Masoudkabir F, Sarrafzadegan N, Eisenberg MJ. Effects of opium consumption on cardiometabolic diseases. Nat Rev Cardiol. 2013;10(12):733–40. doi:10.1038/nrcardio.2013.159.
   PubMed Web of Science ®Google Scholar
• Saadat H, Ziai SA, Ghanemnia M, Namazi MH, Safi M, Vakili H, Dabbagh A, Gholami O. Opium addiction increases interleukin 1 receptor antagonist (IL-1Ra) in the coronary artery disease patients. PLoS One. 2012;7(9):e44939. doi:10.1371/journal.pone.0044939.
   PubMed Web of Science ®Google Scholar
• Leong Abdullah MFI, Tan KL, Narayanan S, Yuvashnee N, Chear NJY, Singh D, Grundmann O, Henningfield JE. Is kratom (Mitragyna speciosa Korth.) use associated with ECG abnormalities? Electrocardiogram comparisons between regular kratom users and controls. Clin Toxicol (Phila)). 2021;59(5):400–8. doi:10.1080/15563650.2020.1812627.
   PubMed Web of Science ®Google Scholar
• Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011-2017. Clin Toxicol (Phila)). 2019;57(10):847–54. doi:10.1080/15563650.2019.1569236.
   PubMed Web of Science ®Google Scholar
• Davidson C, Cao D, King T, Weiss ST, Wongvisavakorn S, Ratprasert N, Trakulsrichai S, Srisuma S. A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017. Am J Drug Alcohol Abuse. 2021;47(1):74–83. doi:10.1080/00952990.2020.1836185.
   PubMed Web of Science ®Google Scholar
• Prevete E, Kuypers KPC, Theunissen EL, Esposito G, Ramaekers JG, Pasquini M, Corazza O. Clinical implications of kratom (Mitragyna speciosa) use: a literature review. Curr Addict Rep. 2023;10(2):317–34. doi:10.1007/s40429-023-00478-3.
   PubMedGoogle Scholar
• Tavakoli HR, et al. Kratom: a new product in an expanding substance abuse market. Fed Pract. 2016;33(11):32–6.
   PubMedGoogle Scholar
• Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo)). 2004;52(8):916–28. doi:10.1248/cpb.52.916.
   PubMed Web of Science ®Google Scholar
• Shellard EJ. The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth. Bull Narc. 1974;26(2):41–55.
   PubMedGoogle Scholar
• Yamamoto LT, Horie S, Takayama H, Aimi N, Sakai S, Yano S, Shan J, Pang PK, Ponglux D, Watanabe K, et al. Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa. Gen Pharmacol. 1999;33(1):73–81. doi:10.1016/s0306-3623(98)00265-1.
   PubMedGoogle Scholar
• Phipps SM, Grundmann O. Chapter 1 - Pharmacology and structure-activity relationship of natural products with psychoactive effects from Salvia divinorum, Mitragyna speciosa, and ayahuasca. In: Atta-ur R., editor. Studies in natural products chemistry;2017. Elsevier, Amsterdam, Netherlands. p. 1–44.
   Google Scholar
• Halpenny GM. Mitragyna speciosa: balancing potential medical benefits and abuse. ACS Med Chem Lett. 2017;8(9):897–9. doi:10.1021/acsmedchemlett.7b00298.
   PubMed Web of Science ®Google Scholar
• Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2019;24(5):874–85. doi:10.1111/adb.12639.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Parthasarathy S, Murugaiyah V, Magosso E, Tan SC, Mansor SM. Understanding the physicochemical properties of mitragynine, a principal alkaloid of Mitragyna speciosa, for preclinical evaluation. Molecules. 2015;20(3):4915–27. doi:10.3390/molecules20034915.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Gassaway MM, Kapoor A, Váradi A, Majumdar S, Filizola M, Javitch JA, Sames D. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138(21):6754–64. doi:10.1021/jacs.6b00360.
   PubMed Web of Science ®Google Scholar
• Giovannitti JA, Jr., Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31–9. doi:10.2344/0003-3006-62.1.31.
   PubMedGoogle Scholar
• Zhang Y, Cuevas S, Asico LD, Escano C, Yang Y, Pascua AM, Wang X, Jones JE, Grandy D, Eisner G, et al. Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure. PLoS One. 2012;7(6):e38745. doi:10.1371/journal.pone.0038745.
   PubMed Web of Science ®Google Scholar
• Watts SW, Davis RP. 5-hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc Ther. 2011;29(1):54–67. doi:10.1111/j.1755-5922.2010.00173.x.
   PubMed Web of Science ®Google Scholar
• Suhaimi FW, Yusoff NHM, Hassan R, Mansor SM, Navaratnam V, Müller CP, Hassan Z. Neurobiology of Kratom and its main alkaloid mitragynine. Brain Res Bull. 2016;126(Pt 1):29–40. doi:10.1016/j.brainresbull.2016.03.015.
   PubMedGoogle Scholar
• Kamble SH, Sharma A, King TI, León F, McCurdy CR, Avery BA. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). Xenobiotica. 2019;49(11):1279–88. doi:10.1080/00498254.2018.1552819.
   PubMed Web of Science ®Google Scholar
• Eggleston W, Stoppacher R, Suen K, Marraffa JM, Nelson LS. Kratom use and toxicities in the United States. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2019;39(7):775–7. doi:10.1002/phar.2280.
   Google Scholar
• Saengmolee W, Cheaha D, Sa-Ih N, Kumarnsit E. Exploring of cardiac autonomic activity with heart rate variability in long-term kratom (Mitragyna speciosa Korth.) users: a preliminary study. PeerJ. 2022;10:e14280. doi:10.7717/peerj.14280.
   PubMed Web of Science ®Google Scholar
• Leong Bin Abdullah MFI, Tan KL, Mohd Isa S, Yusoff NS, Chear NJY, Singh D. Lipid profile of regular kratom (Mitragyna speciosa Korth.) users in the community setting. PLoS One. 2020;15(6):e0234639. doi:10.1371/journal.pone.0234639.
   PubMed Web of Science ®Google Scholar
• Jittasopa W, Srisont S. The causes of death and pathological findings of kratom users: a 5-year retrospective analysis. Am J Forensic Med Pathol. 2021;42(4):335–40. doi:10.1097/PAF.0000000000000691.
   PubMed Web of Science ®Google Scholar
• Singh D, Müller CP, Murugaiyah V, Hamid SBS, Vicknasingam BK, Avery B, Chear NJY, Mansor SM. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia. J Ethnopharmacol. 2018;214:197–206. doi:10.1016/j.jep.2017.12.017.
   PubMed Web of Science ®Google Scholar
• La-Up A, Saengow U, Aramrattana A. High serum high-density lipoprotein and low serum triglycerides in Kratom users: a study of Kratom users in Thailand. Heliyon. 2021;7(4):e06931. doi:10.1016/j.heliyon.2021.e06931.
   PubMed Web of Science ®Google Scholar
• Leong Bin Abdullah MFI, Singh D. Assessment of cardiovascular functioning among regular kratom (Mitragyna speciosa Korth) users: a case series. Front Pharmacol. 2021;12:723567. doi:10.3389/fphar.2021.723567.
   PubMed Web of Science ®Google Scholar
• Theegala V, K Solanki K, S Grover B. Cardiac arrest in a middle-aged woman from combined use of kratom and amphetamine. Chest. 2022;162(4):A776. doi:10.1016/j.chest.2022.08.612.
   Web of Science ®Google Scholar
• Gareeb M, Bhardwaj C, Duvvuri PD. Abstract 10262: high output cardiac failure due to kratom. Circulation. 2022;146(Suppl_1):A10262. doi:10.1161/circ.146.suppl_1.10262.
   Google Scholar
• Sangani V, Sunnoqrot N, Gargis K, Ranabhotu A, Mubasher A, Pokal M. Unusual presentation of kratom overdose with rhabdomyolysis, transient hearing loss, and heart failure. J Investig Med High Impact Case Rep. 2021;9:23247096211005069. doi:10.1177/23247096211005069.
   Web of Science ®Google Scholar
• Sheikh M, Ahmed N, Gandhi H, Chen O. Report of ventricular fibrillation in a 44-year-old man using kratom. BMJ Case Rep. 2021;14(3):e237837. doi:10.1136/bcr-2020-237837.
   PubMedGoogle Scholar
• Patel P, Aknouk M, Keating S, Richard I, Kata P, Ali RY, Cheriyath P. Cheating death: a rare case presentation of kratom toxicity. Cureus. 2021;13(7):e16582. doi:10.7759/cureus.16582.
   PubMed Web of Science ®Google Scholar
• Wong A, Mun M. A case of kratom overdose in a pediatric patient. Case Rep Psychiatry. 2020;2020:8818095.
   PubMedGoogle Scholar
• Wolfer H, Gerona R, Blumenberg A. Evidence of a potential mechanism for Kratom-related cardiac arrest. Clin Toxicol (Phila)). 2020;58(8):851–2. doi:10.1080/15563650.2019.1687907.
   PubMed Web of Science ®Google Scholar
• Abdullah HMA, Haq I, Lamfers R. Cardiac arrest in a young healthy male patient secondary to kratom ingestion: is this ‘legal high’ substance more dangerous than initially thought? BMJ Case Rep. 2019;12(7):e229778. doi:10.1136/bcr-2019-229778.
   PubMedGoogle Scholar
• Palasamudram Shekar S, Rojas EE, D'Angelo CC, Gillenwater SR, Martinez Galvis NP. Legally lethal kratom: a herbal supplement with overdose potential. J Psychoactive Drugs. 2019;51(1):28–30. doi:10.1080/02791072.2018.1562591.
   PubMed Web of Science ®Google Scholar
• Aggarwal G, Robertson E, McKinlay J, Walter E. Death from Kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19(1):61–3. doi:10.1177/1751143717712652.
   PubMedGoogle Scholar
• Ilmie MU, Jaafar H, Mansor SM, Abdullah JM. Subchronic toxicity study of standardized methanolic extract of Mitragyna speciosa Korth in Sprague-Dawley Rats. Front Neurosci. 2015;9:189. doi:10.3389/fnins.2015.00189.
   PubMed Web of Science ®Google Scholar
• Sabetghadam A, Ramanathan S, Sasidharan S, Mansor SM. Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats. J Ethnopharmacol. 2013;146(3):815–23. doi:10.1016/j.jep.2013.02.008.
   PubMed Web of Science ®Google Scholar
• Harizal SN, Mansor SM, Hasnan J, Tharakan JKJ, Abdullah J. Acute toxicity study of the standardized methanolic extract of Mitragyna speciosa Korth in rodent. J Ethnopharmacol. 2010;131(2):404–9. doi:10.1016/j.jep.2010.07.013.
   PubMed Web of Science ®Google Scholar
• Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1):5. doi:10.1186/s41073-019-0064-8.
   PubMedGoogle Scholar
• Anwar M, Law R, Schier J. Notes from the Field: kratom (Mitragyna speciosa) Exposures Reported to Poison Centers - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(29):748–9. doi:10.15585/mmwr.mm6529a4.
   PubMed Web of Science ®Google Scholar
• Bryant HU, Story JA, Yim GK. Morphine-induced alterations in plasma and tissue cholesterol levels. Life Sci. 1987;41(5):545–54. doi:10.1016/0024-3205(87)90406-1.
   PubMed Web of Science ®Google Scholar
• Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. Mayo Clin Proc. 2009;84(3):289–97. doi:10.4065/84.3.289.
   PubMed Web of Science ®Google Scholar
• Naderi GA, et al. Comparing plasma level of CRP, factor VII, fibrinogen platelet counts, systolic and diastolic blood pressure in smokers with opium addicted. J Qazvin Univ Med Sci. 2005;9:3–7.
   Google Scholar
• Nakhaee S, Ghasemi S, Karimzadeh K, Zamani N, Alinejad-Mofrad S, Mehrpour O. The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms. Subst Abuse Treat Prev Policy. 2020;15(1):30. doi:10.1186/s13011-020-00272-8.
   PubMed Web of Science ®Google Scholar
• Sanger DJ, McCarthy PS. Increased food and water intake produced in rats by opiate receptor agonists. Psychopharmacology (Berl)). 1981;74(3):217–20. doi:10.1007/BF00427097.
   PubMed Web of Science ®Google Scholar
• Cumpston KL, Carter M, Wills BK. Clinical outcomes after Kratom exposures: a poison center case series. Am J Emerg Med. 2018;36(1):166–8. doi:10.1016/j.ajem.2017.07.051.
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich)). 2011;13(9):687–9. doi:10.1111/j.1751-7176.2011.00513.x.
   PubMed Web of Science ®Google Scholar
• Hanapi NA, Chear NJ-Y, Azizi J, Yusof SR. Kratom alkaloids: interactions with enzymes, receptors, and cellular barriers. Front Pharmacol. 2021;12:751656. doi:10.3389/fphar.2021.751656.
   PubMed Web of Science ®Google Scholar
• Abou Farha K, Baljé-Volkers C, Tamminga W, den Daas I, van Os S. Dopamine D2R agonist-induced cardiovascular effects in healthy male subjects: Potential implications in clinical settings. ISRN Neurol. 2014;2014:956353–10. doi:10.1155/2014/956353.
   PubMedGoogle Scholar
• Agita A, Alsagaff MT. Inflammation, immunity, and hypertension. Acta Med Indones. 2017;49(2):158–65.
   PubMed Web of Science ®Google Scholar
• Brandes RP. Endothelial dysfunction and hypertension. Hypertension. 2014;64(5):924–8. doi:10.1161/HYPERTEN­SIONAHA.114.03575.
   PubMed Web of Science ®Google Scholar
• Lu J, Wei H, Wu J, Jamil MFA, Tan ML, Adenan MI, Wong P, Shim W. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PLoS One. 2014;9(12):e115648. doi:10.1371/journal.pone.0115648.
   PubMed Web of Science ®Google Scholar
• Behzadi M, Joukar S, Beik A. Opioids and cardiac arrhythmia: a literature review. Med Princ Pract. 2018;27(5):401–14. doi:10.1159/000492616.
   PubMed Web of Science ®Google Scholar
• Kong WM, Chik Z, Ramachandra M, Subramaniam U, Aziddin RER, Mohamed Z. Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules. 2011;16(9):7344–56. doi:10.3390/molecules16097344.
   PubMed Web of Science ®Google Scholar
• Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, Schifano F, Sikka K, Körber S, Hendricks A, et al. Characteristics of deaths associated with kratom use. J Psychopharmacol. 2019;33(9):1102–23. doi:10.1177/0269881119862530.
   PubMed Web of Science ®Google Scholar
• Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, Sukasem C, Wananukul W. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421–9. doi:10.2147/DDDT.S79658.
   PubMed Web of Science ®Google Scholar